Life Science Today

Originally Published as The Niche Podcast

This week, approvals for sleep and seizures across the pond, mRNA finds other SPACs, senior notes for CROs, FTC does a double take, IPOs, and boosters

Find out more at
https://thenichepod.com

Story References
https://tinyurl.com/Niche-064-1
https://tinyurl.com/Niche-064-2
https://tinyurl.com/Niche-064-3
https://tinyurl.com/Niche-064-4
https://tinyurl.com/Niche-064-5
https://tinyurl.com/Niche-064-6
https://tinyurl.com/Niche-064-7

Music by Luke Goodson
https://www.soundcloud.com/lukegoodson

Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.

Originally Published as The Niche Podcast

Device acquisitions, rare disease approvals, COVID success stories, and clinical research ups and downs.

Find out more at
https://thenichepod.com

Story References
https://tinyurl.com/Niche-063-1
https://tinyurl.com/Niche-063-2
https://tinyurl.com/Niche-063-3
https://tinyurl.com/Niche-063-4
https://tinyurl.com/Niche-063-5
https://tinyurl.com/Niche-063-6
https://tinyurl.com/Niche-063-7
https://tinyurl.com/Niche-063-8
https://tinyurl.com/Niche-063-9
https://tinyurl.com/Niche-063-10

Music by Luke Goodson
https://www.soundcloud.com/lukegoodson

Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.

Originally Published as The Niche Podcast

This week, look closer – with drops, controlled gene therapy, acquisitions in antibodies, new antifungals, new biosimilars, and several IPOs

Find out more at
https://thenichepod.com

Story References
https://tinyurl.com/Niche-061-1
https://tinyurl.com/Niche-061-2
https://tinyurl.com/Niche-061-3
https://tinyurl.com/Niche-061-4
https://tinyurl.com/Niche-061-5
https://tinyurl.com/Niche-061-6
https://tinyurl.com/Niche-061-7
https://tinyurl.com/Niche-061-8

Music by Luke Goodson
https://www.soundcloud.com/lukegoodson

About the Show
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.

Originally Published as The Niche Podcast

In this special bonus episode, Dr. Noah Goodson sits down with biotech founders Dr. Shawn Carbonell and Dr. Brent Witgen to discuss their new founder-friendly biotech incubator Brazen Bio.

Find out more at
https://thenichepod.com

Story References
https://wefunder.com/brazenbio/
https://www.linkedin.com/company/brazenbio/
https://www.brazen.bio

Music by Luke Goodson
https://www.soundcloud.com/lukegoodson


Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.

Originally Published as The Niche Podcast

Sequencing technology, decentralized Alzheimer’s trials, busts in gene therapy and microbiomes, and a $2.4B oncology collaboration

 Find out more at
https://thenichepod.com

Story References
https://tinyurl.com/Niche-060-1
https://tinyurl.com/Niche-060-2
https://tinyurl.com/Niche-060-3
https://tinyurl.com/Niche-060-4
https://tinyurl.com/Niche-060-5

Music by Luke Goodson
https://www.soundcloud.com/lukegoodson

Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.

Originally Published as The Niche Podcast

Dopamine deals, Merck vaccine approval, Epipen settlements, billions in buildings, and outsized Oncology IPO.


Story References
https://tinyurl.com/Niche-059-1
https://tinyurl.com/Niche-059-2
https://tinyurl.com/Niche-059-3
https://tinyurl.com/Niche-059-4
https://tinyurl.com/Niche-059-5
https://tinyurl.com/Niche-059-6
https://tinyurl.com/Niche-059-7


Music by Luke Goodson
https://www.soundcloud.com/lukegoodson


Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.

Originally Published as The Niche Podcast

Muddy waters of data privacy and genetic databases, antibody-drug conjugate approvals, unabetted wild enthusiasm for CROs, and mobile MRIs go public.

Story References
https://tinyurl.com/Niche-058-1
https://tinyurl.com/Niche-058-2
https://tinyurl.com/Niche-058-3
https://tinyurl.com/Niche-058-4
https://tinyurl.com/Niche-058-5

Music by Luke Goodson
https://www.soundcloud.com/lukegoodson


About The Niche Podcast

Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.

Originally Published as The Niche Podcast

Welcome to a special bonus episode as we kick off Season 2 the Niche Podcast. I sat down with Dr. Jayne Morgan, the head of the COVID19 task force at Piedmont Healthcare to talk about her career in clinical research. 

Sponsors
https://www.thescopemethod.com

Dr. Morgan on LinkedIn
https://tinyurl.com/Niche-057-1

Dr. Morgan on Instagram
https://tinyurl.com/Niche-057-2

Music by Luke Goodson
https://www.soundcloud.com/lukegoodson


About The Niche Podcast

Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.

Originally Published as The Niche Podcast

This is the last episode of Season 1 of the Niche Podcast. In line with that, I’ve got some announcements right at the top of the episode. Also, this week, congressional brakes, internal brakes, FDA brakes, and the first human CRISPR data.

Story References
https://tinyurl.com/Niche-056-1
https://tinyurl.com/Niche-056-2
https://tinyurl.com/Niche-056-3
https://tinyurl.com/Niche-056-4

Music by Luke Goodson
https://www.soundcloud.com/lukegoodson


Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.

Originally Published as The Niche Podcast

Kidney research, pet health, manufacturing is valuable, and a couple of biotech IPOs

Sponsors
https://www.thescopemethod.com

Story References
https://tinyurl.com/Niche-055-1
https://tinyurl.com/Niche-055-2
https://tinyurl.com/Niche-055-3
https://tinyurl.com/Niche-055-4
https://tinyurl.com/Niche-055-5

Music by Luke Goodson
https://www.soundcloud.com/lukegoodson

Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.